(Q44298506)

1 December 2017

title

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study (English)

1 reference

1 December 2017

0 references

Per Soelberg Sørensen

6

object named as

Per Soelberg Sørensen

1 reference

1 December 2017

1

Giancarlo Comi

1 reference

1 December 2017

3

Gavin Giovannoni

1 reference

1 December 2017

Stuart D Cook

2

1 reference

1 December 2017

Kottil Rammohan

4

1 reference

1 December 2017

Peter Rieckmann

5

1 reference

1 December 2017

Patrick Vermersch

7

1 reference

1 December 2017

Anthony C Hamlett

8

1 reference

1 December 2017

Vissia Viglietta

9

1 reference

1 December 2017

Steven J Greenberg

10

1 reference

1 December 2017

publication date

21 December 2012

1 reference

1 December 2017

1 reference

1 December 2017

volume

260

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

1136-1146

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-012-6775-0

1 December 2017

exact match

0 references

cites work

The place of MRI in monitoring the individual MS patient

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Predicting short-term disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Cladribine: mode of action and implications for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Current and future disease-modifying therapies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

T2 lesions and rate of progression of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Glatiramer acetate in multiple sclerosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

New options for early treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6775-0

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

21 January 2018

1 reference

12 December 2020

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

1 reference

12 December 2020

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

12 December 2020

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

12 December 2020

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

1 reference

12 December 2020

10.1007/S00415-012-6775-0

Identifiers

DOI

1 reference

1 December 2017

1 reference